Document is current
Any future updates will be listed below
-
Authors
LaFlamme, Christy W. http://orcid.org/0000-0002-0808-3475
Rastin, Cassandra http://orcid.org/0009-0006-7622-2111
Sengupta, Soham
Pennington, Helen E. http://orcid.org/0009-0004-6534-5859
Russ-Hall, Sophie J. http://orcid.org/0000-0002-4809-9340
Schneider, Amy L. http://orcid.org/0000-0001-5260-7187
Bonkowski, Emily S.
Almanza Fuerte, Edith P.
Allan, Talia J. http://orcid.org/0000-0002-0970-6750
Zalusky, Miranda Perez-Galey http://orcid.org/0000-0002-4721-7499
Goffena, Joy http://orcid.org/0000-0002-2346-2879
Gibson, Sophia B. http://orcid.org/0000-0001-9839-9045
Nyaga, Denis M. http://orcid.org/0000-0001-6240-4017
Lieffering, Nico
Hebbar, Malavika
Walker, Emily V. http://orcid.org/0000-0003-4880-1483
Darnell, Daniel
Olsen, Scott R.
Kolekar, Pandurang http://orcid.org/0000-0003-0044-0076
Djekidel, Mohamed Nadhir
Rosikiewicz, Wojciech http://orcid.org/0000-0001-7031-3430
McConkey, Haley
Kerkhof, Jennifer http://orcid.org/0000-0003-1245-6606
Levy, Michael A.
Relator, Raissa
Lev, Dorit
Lerman-Sagie, Tally
Park, Kristen L. http://orcid.org/0000-0001-5527-3047
Alders, Marielle http://orcid.org/0000-0002-7386-4868
Cappuccio, Gerarda
Chatron, Nicolas http://orcid.org/0000-0003-0538-0981
Demain, Leigh
Genevieve, David http://orcid.org/0000-0001-6928-6287
Lesca, Gaetan http://orcid.org/0000-0001-7691-9492
Roscioli, Tony http://orcid.org/0000-0003-1502-5000
Sanlaville, Damien
Tedder, Matthew L.
Gupta, Sachin
Jones, Elizabeth A.
Weisz-Hubshman, Monika
Ketkar, Shamika
Dai, Hongzheng
Worley, Kim C. http://orcid.org/0000-0002-0282-1000
Rosenfeld, Jill A. http://orcid.org/0000-0001-5664-7987
Chao, Hsiao-Tuan http://orcid.org/0000-0002-2854-5470
,
Neale, Geoffrey http://orcid.org/0000-0003-3776-0858
Carvill, Gemma L. http://orcid.org/0000-0003-4945-3628
,
Wang, Zhaoming http://orcid.org/0000-0001-7556-3869
Berkovic, Samuel F. http://orcid.org/0000-0003-4580-841X
Sadleir, Lynette G.
Miller, Danny E.
Scheffer, Ingrid E.
Sadikovic, Bekim http://orcid.org/0000-0001-6363-0016
Mefford, Heather C. http://orcid.org/0000-0001-7188-522X
-
Funding
Funding for this research was provided by:
Citizens United for Research in Epilepsy
- License Information
-
More Information
Article History
Received: 20 October 2023
Accepted: 28 June 2024
First Online: 6 August 2024
Competing interests
: B.S. is a shareholder in EpiSign Inc, a company involved in commercialization of EpiSign<sup>TM</sup> software. D.E.M. is on a scientific advisory board at ONT and has received travel support from ONT to speak on their behalf. D.E.M. is engaged in a research agreement with ONT. D.E.M. holds stock options in MyOme. I.E.S. has served on scientific advisory boards for BioMarin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Nutricia, Rogcon, Takeda Pharmaceuticals, UCB, Xenon Pharmaceuticals, Cerecin; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova, Nutricia, Zuellig Pharma, Stoke Therapeutics and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin, Encoded Therapeutics Stoke Therapeutics and Eisai; has served as an investigator for Anavex Life Sciences, Cerevel Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix and Zynerba; has consulted for Care Beyond Diagnosis, Epilepsy Consortium, Atheneum Partners, Ovid Therapeutics, UCB, Zynerba Pharmaceuticals, BioMarin, Encoded Therapeutics and Biohaven Pharmaceuticals; and is a Non-Executive Director of Bellberry Ltd and a Director of the Australian Academy of Health and Medical Sciences and the Australian Council of Learned Academies Limited. I.E.S. may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for <i>SCN1A</i> testing held by Bionomics Inc and licensed to various diagnostic companies; has a patent molecular diagnostic/theragnostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009). L.G.S. receives funding from the Health Research Council of New Zealand and Cure Kids New Zealand, is a consultant for the Epilepsy Consortium, and has received travel grants from Seqirus and Nutricia. L.G.S. has received research grants and consultancy fees from Zynerba Pharmaceuticals and has served on Takeda and Eisai Pharmaceuticals scientific advisory panels. The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing conducted at Baylor Genetics Laboratories. The remaining authors declare no competing interests.
